HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44

Benzinga · 04/07 11:22
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $44.